P1784

Pentoxifylline

solid

• Sinonimo/i: 3,7-Dimethyl-1-(5-oxohexyl)xanthine, Trental
• Formula empirica (notazione di Hill): C₁₃H₁₈N₄O₃
• Numero CAS: 6493-05-6
• Peso molecolare: 278.31
• Numero CE: 229-374-5
• Numero MDL: MFCD00063379
• Codice UNSPSC: 41106305
• ID PubChem: 24278190

Proprietà

• Forma fisica: solid
• Livello qualitativo: 100
• Colore: white
• Solubilità: H₂O: ≥43 mg/mL, colorless to almost colorless
• Ideatore: Sanofi Aventis
• Stringa SMILE: CN1C=NC2C1C(=O)N(CCCCC(C)=O)C(=O)N2C
• InChI: 1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8,10-11H,4-7H2,1-3H3; MQGNNJQTNFHNHK-UHFFFAOYSA-N
• Informazioni sul gene: human ... ADORA2B(136) , LITAF(9516) , PDE4B(5142) , TNF(7124) ; rat ... Tnf(24835)

Descrizione

Applicazioni

Pentoxifylline has been used:

• used in the combinatorial treatment with itraconazole for paracoccidioidomycosis (PCM)
• to treat harvested sperms to check the effect of ′pentoxifylline exposed sperms′ in the contribution of embryonic growth
• to intrathecally inject female and male mice to investigate whether astrocytes and microglia could be causally involved in the maintenance of pain-like behaviour

Azioni biochim/fisiol

Pentoxifylline (PTX) is considered as a nonspecific phosphodiesterase inhibitor. It possesses rheologic properties. Pentoxifylline is used to treat peripheral vascular disease. It has the ability to block the phosphorylation of I kappa B-alpha (IĸBα) in serines 32 and 36.

Phosphodiesterase inhibitor; inhibits synthesis of tumor necrosis factor α (TNF-α).

Caratteristiche e vantaggi

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Histamine Synthesis and Metabolism and Phosphodiesterases pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.